Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma

Clinical Trial ID NCT01729806

PubWeight™ 6.30‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01729806

Top papers

Rank Title Journal Year PubWeight™‹?›
1 At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013 1.90
2 Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy. Oncoimmunology 2014 1.22
3 Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". Toxins (Basel) 2014 0.92
4 The past, present and future of immunotherapy against tumor. Transl Lung Cancer Res 2015 0.85
5 Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy. Pharmaceuticals (Basel) 2015 0.78
6 Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet? Bone Marrow Transplant 2015 0.77
Next 100